Last year's first quarter saw a flurry of biotech takeover deals, starting off with Johnson & Johnson (JNJ)/Ambrx, Merck (MRK)/Harpoon, GSK (GSK)/Aiolos and Novartis(NVS)/Calypso in early January.
Qure (NASDAQ:QURE – Get Free Report) shares gapped down before the market opened on Friday . The stock had previously closed at $18.05, but opened at $17.55. uniQure shares last traded at $17.73, with ...
Sangamo (SGMO) stock faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price ...
Across 2024, more than 4,940 workers lost their jobs at Massachusetts life sciences companies. The Business Journal has a ...
Qure (NASDAQ:QURE – Get Free Report) shares were up 5.8% during mid-day trading on Friday after Mizuho raised their price ...
uniQure (NASDAQ:QURE – Get Free Report) had its price target boosted by research analysts at Mizuho from $7.00 to $20.00 in a report issued on Thursday,Benzinga reports.The firm presently has a ...
Bullish option flow detected in uniQure (QURE) with 6,527 calls trading, 2x expected, and implied vol increasing over 14 points to 82.58%. Jan-25 17 calls and Jan-25 22 calls are the most active ...
On Thursday, Mizuho (NYSE:MFG) Securities updated its perspective on uniQure BV (NASDAQ:QURE), a biotechnology company specializing in gene therapy. The firm increased its price target for uniQure's ...
On Thursday, Mizuho (NYSE:MFG) Securities updated its perspective on uniQure BV (NASDAQ:QURE), a biotechnology company specializing in gene therapy. The firm increased its price target for uniQure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback